Browse > Article
http://dx.doi.org/10.4333/KPS.2008.38.2.127

Preparation of Lipid Nanoparticles Containing Paclitaxel and their in vitro Gastrointestinal Stability  

Kim, Eun-Hye (Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology)
Lee, Jung-Eun (Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology)
Lim, Deok-Hwi (Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology)
Jung, Suk-Hyun (Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology)
Seong, Ha-Soo (Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology)
Park, Eun-Seok (College of Pharmacy, Sungkyunkwan University)
Shin, Byung-Cheol (Center for Drug Discovery Technology, Korea Research Institute of Chemical Technology)
Publication Information
Journal of Pharmaceutical Investigation / v.38, no.2, 2008 , pp. 127-134 More about this Journal
Abstract
Peroral administration is the most convenient one for the administration of pharmaceutically active compounds. Most of poorly water-soluble drugs administered via the oral route, however, remain poorly available due to their precipitation in the gastrointestinal (GI) tract and low permeability through intestinal mucosa. In this study, one of drug delivery carriers, lipid nanoparticles (LNPs) were designed in order to reduce side effects and improve solubility and stability in GI tract of the poorly water soluble drugs. However, plain LNPs are generally unstable in the GI tract and susceptible to the action of acids, bile salts and enzymes. Accordingly, the surface of LNPs was modified with polyethylene glycol (PEG) for the purpose of improving solubility and GI stability of paclitaxel (PTX) in vitro. PEG-modified LNPs containing PTX was prepared by spontaneous emulsification and solvent evaporation (SESE) method and characterized for mean particle diameter, entrapping efficiency, zeta potential value and in vitro GI stability. Mean particle diameter and zeta potential value of PEG-modified LNP containing PTX showed approximately 86.9 nm and -22.9 mV, respectively. PTX entrapping efficiency was about 70.5% determined by UV/VIS spectrophotometer. Futhermore, change of particle diameter of PTX-loaded PEG-LNPs in simulated GI fluids and bile fluid was evaluated as a criteria of GI stability. Particle diameter of PTX-loaded PEG-LNPs were preserved under 200 nm for 6 hrs in simulated GI fluids and bile fluid at $37^{\circ}C$ when DSPE-mPEG2000 was added to formulation of LNPs above 4 mole ratio. As a result, PEG-modified LNPs improved stability of plain LNPs that would aggregate in simulated GI fluids and bile solution. These results indicate that LNPs modified with biocompatible and nontoxic polymer such as PEG might be useful for enhancement of GI stability of poorly water-soluble drugs and they might affect PTX absorption affirmatively in gastrointestinal mucosa.
Keywords
Oral administration; Lipid nanoparticles; Paclitaxel; Stability; Polyethylene glycol;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 W.R. Rerkins, I. Ahmad, X. Li, D.J. Hirsh, G.R. Masters, C.J. Fecko, J.K. Lee, S. Ali, J. Nguyen, J. Schupsky, C. Herbert, A.S. Janoff and E. Mayhew, Novel therapeutic nano-particles (lipocores): trapping poorly water soluble compounds, Int. J. Pharm., 200, 27-39 (2000)   DOI   ScienceOn
2 G. Suresh, K. Manjunath, V. Venkateswarlu and V. Satyanarayana, Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles, AAPS Pharm. Sci. Tech., 8(1) article 24 (2007)
3 M.D. Chavanpatil, Y. Pati and J. Panyama, Susceptibility of nanoparticle encapsulated paclitaxel to p-glycoproteinmediated drug efflux, Int. J. Pharm., 320, 150-156 (2006)   DOI   ScienceOn
4 S.H. Jung, J.E. Lee, H. Seong and B.C. Shin, Preparation of the dexamethasone-incorporated lipid nanosphere: Characteristics of lipid nanosphere by varying species and ratio of lipid, J. Kor. Chem. Soc., 50, 464-470 (2006)   DOI
5 R.B. Greenwald, Y.H. Choe, J. McGuire and C.D. Conover, Effective drug delivery by PEGylated drug conjugates, Adv. Drug Deli. Rev., 55, 217-250 (2003)   DOI   ScienceOn
6 S.A. Wissing, O. Kayser and R.H. Müller, Solid lipid nanoparticles for parenteral drug delivery, Adv. Drug Deli. Rev., 56, 1257-1272 (2004)   DOI   ScienceOn
7 M. Trotta, F. Debernardi and O. Caputo, Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique, Int. J. Pharm., 257, 153-160 (2003)   DOI   ScienceOn
8 M. Rawat, D. Singh, S. Saraf and S. Safar, Nanocarriers: Promising vehicle for bioactive drugs, Biol. Pharm. Bull., 29, 1790-1798 (2006)   DOI   ScienceOn
9 A.K. Singla, A. Garg and D. Aggarwal, Paclitaxel and its formulations, Int. J. Pharm., 235, 179-192 (2002)   DOI   ScienceOn
10 C.M. Lee, H.C. Lee and K.Y. Lee, O-palmitoylcurdlan surface (OPCurS)-coated liposomes for oral drug delivery, J. Biosci. Bioeng., 100, 255-259 (2005)   DOI   ScienceOn
11 S.K. Kumar, S.A. Williams, J.T. Isaacs, S.R. Denmeade and S.R. Khan, Modulating paclitaxel bioavailability for targeting prostate cancer, Bioorg. Med. Chem., 15, 4973-4984 (2007)   DOI   ScienceOn
12 S.S. Feng and G. Haung, Effects of emulsifiers on the controlled release of paclitaxel(Taxol) from nanospheres of biodegradable polymers, J. Control. Release, 71, 53-69 (2001)   DOI   ScienceOn
13 P. Labrie, S.P. Maddaford, J. Lacroix, C. Catalano, D.K.H. Lee, S. Rakhit and R.C. Gaudreault, In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity at CYP-450, Bioorg. Med. Chem., 14 7972-7987 (2006)   DOI   ScienceOn
14 S. Peltier, J.M. Oger, F. Lagarce, W. Couet and J.P. Benoît, Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules, Pharm. Res., 23, 1243-1250 (2006)   DOI
15 S.H. Jung, J.E. Lee, H. Seong and B.C. Shin, Preparation of dexamethasone-21-palmitate incorporated lipid nanosphere: Physical properties by varying components and ratio of lipid, J. Kor. Pharm. Sci., 36, 224-261 (2006)   DOI
16 H. Ohvo-Rekila, B. Ramstedt, P.L. ki and J.P. Slotte, Cholesterol interactions with phospholipids in membranes, Prog. Lipid Res., 41, 66-97 (2002)   DOI   ScienceOn
17 M.N. Magomedov, Dependence of the surface energy on the size and shape of a nanocrystal, Phys. Solid State, 46, 954-968 (2004)   DOI
18 R.L. Hong, C.J. Huang, Y.L. Teng, V.F. Pang, S.T. Chen, J.J. Liu and F.H. Chang, Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice, Clin. Cancer Res., 5, 3645-3652 (1999)
19 E. Zimmermann and R.H. Müller, Electrolyte- and pHstabilities of aqueous solid lipid nanoparticle ($SLN^{TM}$) dispersions in artificial gastrointestinal media, Eur. J. Pharm. Biopharm., 52, 203-210 (2001)   DOI   ScienceOn
20 V.M. Samsonov, N.Y. Sdobnyakov and A.N. Bazulev, Size dependence of the surface tension and the problem of Gibbs thermodynamics extension to nanosystems, Colloids and Surfaces, 239, 113-117 (2004)   DOI   ScienceOn
21 Y. Hu, J. Xie, Y.W. Tong and C.H. Wang, Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells, J. Control. Release, 118, 7-17 (2007)   DOI   ScienceOn